Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 4, 2014, Pages 558-565

  Hartner, Andrea ^a   Cordasic, Nada ^a   Klanke, Bernd ^a   Menendez Castro, Carlos ^a   Veelken, Roland ^a   Schmieder, Roland E ^a   Hilgers, Karl F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angiotensin receptor antagonist; Diabetic nephropathy; ER stress; Inflammation; Irbesartan

Indexed keywords

GLUCOSE; IRBESARTAN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CELL PROLIFERATION; DIABETIC NEPHROPATHY; ENDOPLASMIC RETICULUM STRESS; GLOMERULOSCLEROSIS; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; KIDNEY INJURY; LOW DRUG DOSE; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION;

ANGIOTENSIN RECEPTOR ANTAGONIST; DIABETIC NEPHROPATHY; ER STRESS; INFLAMMATION; IRBESARTAN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; ENDOPLASMIC RETICULUM STRESS; INFLAMMATION; KIDNEY; MALE; RATS; SMAD PROTEINS; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84893431853     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.01.001     Document Type: Article

References (41)

1. Ritz E., Orth S.R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1999, 341:1127-1133.
2. Cunard R., Sharma K. The endoplasmic reticulum stress response and diabetic kidney disease. Am. J. Physiol. Ren. Physiol. 2011, 300:F1054-F1061.
3. Kozutsumi Y., Segal M., Normington K., Gething M.J., Sambrook J. The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature 1988, 332:462-464.
4. Inagi R. Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury. Nephrol. Exp. Nephrol. 2009, 112:e1-e9.
5. Lindenmeyer M.T., Rastaldi M.P., Ikehata M., Neusser M.A., Kretzler M., Cohen C.D., Schlondorff D. Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J. Am. Soc. Nephrol.: JASN 2008, 19:2225-2236.
6. Liu G., Sun Y., Li Z., Song T., Wang H., Zhang Y., Ge Z. Apoptosis induced by endoplasmic reticulum stress involved in diabetic kidney disease. Biochemical and biophysical research communications 2008, 370:651-656.
7. Inoki K., Mori H., Wang J., Suzuki T., Hong S., Yoshida S., Blattner S.M., Ikenoue T., Ruegg M.A., Hall M.N., Kwiatkowski D.J., Rastaldi M.P., Huber T.B., Kretzler M., Holzman L.B., Wiggins R.C., Guan K.L. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest. 2011, 121:2181-2196.
8. Lakshmanan A.P., Thandavarayan R.A., Palaniyandi S.S., Sari F.R., Meilei H., Giridharan V.V., Soetikno V., Suzuki K., Kodama M., Watanabe K. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice. Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 2011, 44:627-634.
9. Sun H.L., Sun L., Li Y.Y., Shao M.M., Cheng X.Y., Ge N., Lu J.D., Li S.M. ACE-inhibitor suppresses the apoptosis induced by endoplasmic reticulum stress in renal tubular in experimental diabetic rats. Exp. Clin. Endocrinol. Diabetes: Off. J., Ger. Soc. Endocrinol. German Diabetes Assoc. 2009, 117:336-344.
10. Kelly D.J., Wilkinson-Berka J.L., Allen T.J., Cooper M.E., Skinner S.L. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int. 1998, 54:343-352.
11. Hartner A., Cordasic N., Klanke B., Wittmann M., Veelken R., Hilgers K.F. Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. Am. J. Physiol. Ren. Physiol. 2007, 292:F820-F827.
12. Appelhoff R.J., Hill J.V., Findon G., Frampton C.M., Perry E., Ponnamperuma D., Endre Z.H. Differential contribution of diabetes and the Ren2 gene to glomerular pathology in diabetic (mREN-2)27 rats. Lab. Invest. 2010, 90:1225-1235.
13. Wilkinson-Berka J.L., Gibbs N.J., Cooper M.E., Skinner S.L., Kelly D.J. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol. Dial. Transplant. 2001, 16:1343-1349.
14. Kelly D.J., Skinner S.L., Gilbert R.E., Cox A.J., Cooper M.E., Wilkinson-Berka J.L. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int. 2000, 57:1882-1894.
15. Tuncdemir M., Ozturk M. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acta Histochem. 2011, 113:826-832.
16. Gonzalez-Albarran O., Gomez O., Ruiz E., Vieitez P., Garcia-Robles R. Role of systolic blood pressure on the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats). Am. J. Hypertens. 2003, 16:979-985.
17. Ren X., Guan G., Liu G., Liu G. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats. Pharmacology 2009, 83:80-87.
18. Vieitez P., Gomez O., Uceda E.R., Vera M.E., Molina-Holgado E. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J. Renin-Angiotensin-Aldosterone Syst. JRAAS 2008, 9:96-102.
19. O'Donnell M.P., Crary G.S., Oda H., Kasiske B.L., Powell J.R., Keane W.F. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int. Suppl. 1997, 63:S218-S220.
20. Hartner A., Porst M., Gauer S., Prols F., Veelken R., Hilgers K.F. Glomerular osteopontin expression and macrophage infiltration in glomerulosclerosis of DOCA-salt rats. Am. J. Kidney Dis. 2001, 38:153-164.
21. Daniel C., Schaub K., Amann K., Lawler J., Hugo C. Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 2007, 56:2982-2989.
22. Hayakawa K., Hiramatsu N., Okamura M., Yao J., Paton A.W., Paton J.C., Kitamura M. Blunted activation of NF-kappaB and NF-kappaB-dependent gene expression by geranylgeranylacetone: involvement of unfolded protein response. Biochem. Biophys. Res. Commun. 2008, 365:47-53.
23. Lee W.H., Akatsuka S., Shirase T., Dutta K.K., Jiang L., Liu Y.T., Onuki J., Yamada Y., Okawa K., Wada Y., Watanabe A., Kohro T., Noguchi N., Toyokuni S. Alpha-tocopherol induces calnexin in renal tubular cells: another protective mechanism against free radical-induced cellular damage. Arch. Biochem. Biophys. 2006, 453:168-178.
24. Nyengaard J.R., Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993, 36:189-194.
25. Ziyadeh F.N. Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J. Am. Soc. Nephrol. 2004, 15(Suppl. 1):S55-S57.
26. Lee H.S. Pathogenic role of TGF-beta in the progression of podocyte diseases. Histol. Histopathol. 2011, 26:107-116.
27. Massague J. TGF-beta signal transduction. Ann. Rev. Biochem. 1998, 67:753-791.
28. Lewis E.J. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am. J. Hypertens. 2002, 15:123S-128S.
29. Liu B.C., Chen Q., Luo D.D., Sun J., Phillips A.O., Ruan X.Z., Liu N.F. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol. Sin. 2003, 24:67-73.
30. Xie H.H., Shen F.M., Zhang X.F., Jiang Y.Y., Su D.F. Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs. Eur. J. Pharmacol. 2006, 543:77-82.
31. Jover B., Herizi A., Casellas D., Mimran A. Influence of irbesartan and enalapril on changes of renal function associated with the established phase of L-NAME hypertension. Int. J. Hypertens. 2001, 19:2039-2046.
32. Klanke B., Cordasic N., Hartner A., Schmieder R.E., Veelken R., Hilgers K.F. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. Nephrol. Dial. Transplant. 2008, 23:3456-3463.
33. Hartner A., Veelken R., Wittmann M., Cordasic N., Hilgers K.F. Effects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney. BMC Nephrol. 2005, 6:6.
34. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., Han K.H., Kim H.K., Kang Y.S., Han J.Y., Kim Y.S., Cha D.R. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol.: JASN 2006, 17:1362-1372.
35. Sasser J.M., Sullivan J.C., Hobbs J.L., Yamamoto T., Pollock D.M., Carmines P.K., Pollock J.S. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol.: JASN 2007, 18:143-154.
36. Galkina E., Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol.: JASN 2006, 17:368-377.
37. Mezzano S., Droguett A., Burgos M.E., Ardiles L.G., Flores C.A., Aros C.A., Caorsi I., Vio C.P., Ruiz-Ortega M., Egido J. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int. Suppl. 2003, S64-S70.
38. de Vinuesa S.G., Goicoechea M., Kanter J., Puerta M., Cachofeiro V., Lahera V., Gomez-Campdera F., Luno J. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J. Am. Soc. Nephrol.: JASN 2006, 17:S206-S212.
39. Tu X., Chen X., Xie Y., Shi S., Wang J., Chen Y., Li J. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J. Am. Soc. Nephrol.: JASN 2008, 19:77-83.
40. Giachelli C.M., Lombardi D., Johnson R.J., Murry C.E., Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 1998, 152:353-358.
41. Fougeray S., Bouvier N., Beaune P., Legendre C., Anglicheau D., Thervet E., Pallet N. Metabolic stress promotes renal tubular inflammation by triggering the unfolded protein response. Cell Death Dis. 2011, 2:e143.